Predicting Factors for a Favorable Pathologic Response to Neoadjuvant Therapy in Esophageal Cancer. (2nd December 2022)

• Record Type: Journal Article
• Authors: Wiesel, Ory; Zlotnik, Oran; Morgenstern, Sarah; Tsur, Maya; Menasherov, Nikolai; Feferman, Yael; Ben-Aharon, Irit; Kashtan, Hanoch
• Is Part Of: American journal of clinical oncology. Volume 45:Number 12(2022)
• Page Start: 514
• Page End: 518
• Publication Date: 2022-12-02
• Subjects: esophageal cancer -- gastroesophageal junction cancer -- tumor regression grade -- favorable pathologic response -- esophagectomy; Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0000000000000954
• Languages: English
• ISSNs: 0277-3732

Abstract

Abstract : Background: Favorable pathologic response(FPR) is a significant predictor for improved survival following Neoadjuvant therapy(NAT) in esophageal and gastroesophageal cancer(GEJ). Preoperative prediction of FPR could modify treatment plans. No reliable method for predicting FPR exists. We sought to identify preoperative predicting factors for FPR. Materials and Methods: Retrospective analysis of patients with esophageal and GEJ cancer who underwent esophagectomy following (NAT). Univariate and multivariate analysis was used to identify preoperative predicting factors for FPR. A comparison of Tumor Regression Grade(TRG) was used to assess treatment response on overall survival(OS). Results: Out of 121 patients, 82(67.8%) had neoadjuvant chemoradiation. FPR was observed in 60(49.6%). Female sex, Radiation therapy(RT), squamous cell carcinoma(SCC), lack of signet ring feature, and FDG avidity posttreatment were associated with FPR on univariate analysis. RT and SCC were associated with FPR (OR=3.9 and 4.0, respectively) on multivariate analysis. OS was lower among patients who did not achieve FPR to NAT( P =0.027). Conclusions: FPR is a predictor of improved OS. SCC and radiation therapy-based protocol were identified as major prediction factors of FPR in patients with esophageal and GEJ cancers.